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Abstract
Hepatoma-derived growth factor (HDGF) is overexpressed in lung cancer and the overexpression
correlates with aggressive biologic behaviors and poor clinical outcomes. We developed anti-
HDGF monoclonal antibodies and tested their anti-tumor activity in lung cancer xenograft models.
We also determined biologic effects in tumors treated with the antibody alone or in combination
with bevacizumab/avastin (an anti-VEGF antibody) and/or gemcitabine (a chemotherapeutic
agent). We found the anti-HDGF was effective to inhibit tumor growth in non-small cell lung
cancer (NSCLC) xenograft models. In the A549 model, comparing to control IgG, tumor growth
was substantially inhibited in animals treated with anti-HDGF antibodies, particularly HDGF-C1
(P = 0.002) and HDGF-H3 (P = 0.005). When HDGF-H3 was combined with either bevacizumab
or gemcitabine, we observed enhanced tumor growth inhibition, particularly when the three agents
were used together. HDGF-H3-treated tumors exhibited significant reduction of microvessel
density with a pattern distinctive from the microvessel reduction pattern observed in bevacizumab-
treated tumors. HDGF-H3 but not bevacizumab treated tumors also showed a significant increase
of apoptosis. Interestingly, many of the apoptotic cells in HDGF-H3-treated tumors are stroma
cells, suggesting the mechanism of the anti-tumor activity is, at least in part, through disrupting
formation of tumor-stroma structures. Our results demonstrate that HDGF is a novel therapeutic
target for lung cancer and can be effectively targeted by an antibody-based approach.
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INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths worldwide (1). Most of the
patients with lung cancer are diagnosed at advanced stage with a median survival <12
months due to lack of effective therapies (2–4). Therefore, development of novel
therapeutics for patients with advanced stage of lung cancer is critically needed.
Hepatoma-derived growth factor (HDGF) is a heparin-binding growth factor identified from
media conditioned by a human hepatoma-derived cell line, and exhibits mitogenic activity to
Request for reprints: Li Mao, M.D., Department of Thoracic/Head and Neck Medical Oncology, Unit 432, The University of Texas M.
D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-6363; Fax: (713) 796-8655; E-mail:
lmao@mdanderson.org.
NIH Public Access
Author Manuscript
Mol Cancer Ther. Author manuscript; available in PMC 2010 November 1.
Published in final edited form as:
Mol Cancer Ther. 2009 May ; 8(5): 1106–1112. doi:10.1158/1535-7163.MCT-08-0779.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
various cell types (5–7). HDGF is highly expressed during embryonic development in
smooth muscle, guts, and endothelium but not after birth (5,8,9). It has also been implicated
in angiogenesis (8). High-level HDGF can be observed in various human cancers including
lung cancer and the overexpression is correlated with poor clinical outcomes (10–14),
suggesting the importance of HDGF in cancer progression. Although the molecular
mechanisms of HDGF in cancer progression are poorly understood, we have previously
showed that HDGF contributes to anchorage independent growth and tumor cell invasion
(15). We further demonstrated that lung cancer cells with down-regulated HDGF formed
significantly smaller tumors in vivo (15), suggesting HDGF may be a therapeutic target.
In this study, we reported an antibody based approach to target HDGF in non-small cell lung
cancer (NSCLC) models.
MATERIALS AND METHODS
Cell lines and culture conditions
Human NSCLC cell lines were grown in monolayer culture in a 1:1 mixture of DMEM and
Ham’s F12 medium supplemented with heat inactivated 5% fetal bovine serum and
antibiotics at 37°C in a humidified atmosphere consisting of 95% air and 5% CO2 unless
indicated otherwise.
Recombinant protein
The cDNA fragment that encodes HDGF was PCR amplified and cloned into pGEX-4-T1
vector (GE Health Care, Piscataway, NJ). The resulted plasmid, pGST-HDGF, was used to
generate GST-HDGF fusion protein in E. Coli strain BL21 (DE3). The recombinant protein
was purified using GST affinity chromatography.
Hybridoma and antibody production
Balb/c mice were immunized with the fusion protein and boosted twice. Three days after the
last boost, mice were sacrificed and spleenocytes were fused with P3X63Ag8.653 cells
followed by culturing in selecting medium. Anti-HDGF antibody secreting hybridoma
clones were identified and verified. For large scale antibody production, hybridoma cells
were cultured in RPMI 1640 supplemented with Nutridoma CS (Roche Applied Science,
Indianapolis, IN). The antibodies were purified using protein G-agarose (GE Health Care)
affinity chromatograph. Purified antibody was then dialyzed and sterile filtered through a
0.22μm filter.
Protein extraction and Western blotting
Log-phase growing NSCLC cells were incubated in PBS with 1% Triton X-100 and protease
inhibitor cocktail (Roche Applied Science). The cell lysates were clarified by centrifugation.
Proteins (10μg) were separated through a 10% polyacrylamide gel and transferred to a
nitrocellulose membrane (Schleicher & Shuell BioScience, Keene, NH). Signal was detected
using an enhanced chemiluminescence kit (Pierce, Rockford, IL).
Immunoprecipitation
Protein extracts were incubated with anti-HDGF antibody immobilized on protein G-agarose
(Sigma, St. Luis, MO) for 2 hrs. Bound proteins were eluted with 2 X SDS-PAGE sample
loading buffer. The eluted proteins were analyzed using SDS-PAGE and Western blotting.
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Immunohistochemistry
Sections (4 μm) were from formalin-fixed and paraffin-embedded tissue blocks or OCT-
embedded frozen tissues. All the sections were mounted on positively charged glass slides.
For formalin-fixed tissues, sections were deparafinized and stained with appropriate
antibody using ABC Elite system (Vector Labs, Burlingame, CA). For frozen tissues, the
sections were fixed with acetone before being processed for staining. Diaminobenzidine was
used as a chromogen and commercial hematoxylin was used for counterstaining. For
microvessel density analysis, CD31 staining was measured using 10X objective
magnification for 3 to 6 randomly selected fields (2.18 mm2 per field). Each field was then
divided into 155 squares (grids). The grids with CD31 staining was counted as positive and
total positive grids divided by the total grids measured was used to calculate percentage of
positive grids for each sample.
TUNEL assay
Tissue sections were incubated with TdT reaction buffer containing 0.2 unit/μl terminal
transferase (New England Biolabs, Ipswich, MA) and 20 μM biotin-16-dUTP (Roche
Applied Science) in a humidify chamber. ABC complex (Vector Labs) was used for signal
development. TUNEL positive cells were counted under a 10 X objective lens. Average of
number of positive TUNEL cells in 3–5 fields was used as TUNEL labeling index.
Tumor xenograft model
Athymic Swiss nu/nu/Ncr nude (nu/nu) mice were used. Briefly, 4-week-old male nude
mice were injected subcutaneously with 4 × 106 cancer cells at a single dorsal site. At day 7,
tumor bearing mice were randomized into experimental groups (5 per group) and treated
with appropriate agents accordingly. Treatment was repeated every 3 days. Tumor size was
measured every 2 days until animals were sacrificed by measuring the tumors in three
dimensions with calipers. At the time of sacrifice, tumors were dissected and weighted.
Statistical analyses
Student T-test was used to determine differences in tumor weight, microvessel density, Ki67
labeling index, and TUNEL labeling index, between tumors treated with control antibody
(M31) and tumors treated with anti-HDGF antibodies or combinations. Student T-test was
also used to determine difference in microvessel density between H3 treated tumors and
combinations. P values smaller than 0.05 are considered statistically significant. For in vivo
tumor growth, the statistical significance of differences in tumor growth was analyzed by
ANOVA using analytical software, STATISTICA (StatSoft, Tulsa, OK).
RESULTS AND DISCUSSION
To explore antibody-based therapeutic strategy, we first generated a panel of anti-HDGF
antibodies (HDGF-C1, -C4, -H3, and -L5–9) capable to bind native HDGF. All the
antibodies are IgG1 and recognize the “classic” HDGF at approximately 38 kDa on Western
blots (Fig. 1A) and the identity of the recognized protein was confirmed by
immunoprecipitation and subsequent two-dimensional gel electrophoresis based Western
blot analysis (Fig. S1). Some of the antibodies can also recognize proteins migrated at 50 to
70 kDa range (Fig. 1A), possibly modified forms of HDGF or HDGF homologues as these
proteins can also be recognized by immunoprecipitation and anti-HDGF antibodies different
from the antibody used for immunoprecipitation (Fig. S1).
To validate that HDGF is secreted or released from lung cancers, we analyzed proteins from
conditioned media of a panel of non-small cell lung cancer (NSCLC), the most common
type of lung cancer, cell lines. HDGF was detected in the conditioned media of every
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NSCLC cell lines (Fig. 1B). Beside the common 38 kDa band, proteins between 38 kDa and
60 kDa were also observed in some of the cell lines (Fig. 1B). The result indicates that most
of the NSCLC cells secret or release substantial amount of HDGF into extracellular space.
Because HDGF can reenter into cells (5) or bind to cell surface receptor (16) to assert its
mitogenic property, neutralizing the extracellular HDGF is a logical strategy to target
HDGF.
To determine distribution of the antibody administered IP, we injected 250μg HDGF-H3 and
M31 antibodies labeled with either Cy3 or Cy5 fluorescence dyes to each mouse bearing
A549 tumors. We first examined the antibody distribution using a whole body imaging
scanner with different filters and found the antibodies were delivered to the entire animal
including the tumors (Fig. 1C). We then examined tumor tissues obtained from the mice
after treatment using a specific anti-mouse IgG1 antibody. While tumors from PBS treated
mice did not show staining as expected, staining was observed in tumors treated with
various antibodies (Fig. 1D), indicating the antibodies were delivered to the tumor tissues.
Interestingly, we observed cytoplasmic staining in both HDGF-C1 and HDGF-H3 treated
tumors, suggesting the antibodies somehow entered into the cells. It was noticed that the
cytoplasmic staining was particularly strong in HDGF-C1 treated cells and the staining
might concentrate in perinuclear and even inside nuclear in some cancer cells (Fig. S2). The
significance of the observation is unclear at this time.
To test the anti-HDGF antibodies in suppressing growth of NSCLC, we evaluated four
antibodies in A549 NSCLC xenograft model. Once tumors formed subcutaneously in nude
mice, we treated the animals with the anti-HDGF antibodies (10mg/kg, every three days) by
intra-peritoneal (IP) injection. Mice treated with the anti-HDGF antibodies showed
significantly slower tumor growth compared to mice treated with controls (Fig. 2A).
Comparing to MOPC-31 (M31), an IgG1 antibody with no know target, tumor growth was
substantially inhibited in animals treated with HDGF-C1 (P = 0.002), HDGF-C4 (P =
0.026), HDGF-H3 (P = 0.005), and HDGF-L5–9 (P = 0.05). The average tumor burdens at
the end of the experiment (22 days after tumor inoculation) were 960 mg for control-IgG
treated mice, compared to 224 mg for HDGF-C1 and 266 mg for HDGF-H3 treated mice,
respectively. Consistent with the tumor growth inhibition, the size and weight of the tumors
were substantially smaller/lighter in the animals treated with the anti-HDGF antibodies (Fig.
2B and 2C). Because of the superior tumor growth inhibition observed in HDGF-C1 and
HDGF-H3 treated animals, the two antibodies were selected for further experimentations. In
the subsequent experiments using H460 NSCLC xenograft model and M109 murine lung
adenocarcinoma model, both HDGF-C1 and HDGF-H3 showed tumor growth inhibition
(data not shown). HDGF-H3 was then selected as the lead antibody for experiments
described below.
We did not observe apparent toxicities including weight loss to the animals during 2 weeks
treatment. At the time of sacrificing animals, we examined gross appearance of major organs
and found no abnormal changes in the antibody treated animals both grossly and
histologically (Fig. S3).
Because HDGF has been suggested to promote angiogenesis independent of VEGF (17,18)
and the cellular HDGF may be released upon damage by cytotoxic agents, we hypothesized
that combining HDGF-H3 antibody with bevacizumab (avastin), a clinically effective VEGF
neutralizing antibody, and/or Gemcitabine (Gem), a chemotherapeutic agent approved for
NSCLC, may have synergy in treating NSCLC. We test the hypothesis using A549 NSCLC
xenogrraft model. Comparing to M31 control, both HDGF-H3 and bevacizumab
significantly inhibited tumor growth (Fig. 2D, P = 0.0002 and P < 0.0001, respectively)
whereas Gem showed only a modest tumor growth inhibition (P = 0.23). When Gem was
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co-administered with HDGF-H3, however, tumors grown slower than those treated with
Gem alone. The average final tumor burden was 279mg in the Gem and HDGF-H3 treated
animals compared to 500mg in the Gem alone animals, although the difference did not reach
statistical significance (P = 0.13). However, the inhibition by the two agent combination was
only slightly greater compared to HDGF-H3 treatment alone (375 mg average tumor
burden), suggesting the effect is mainly due to HDGF-H3. When Gem, HDGF-H3, and
bevacizumab were administered together, we observed statistically significant tumor growth
inhibition compared to any of the two-agent combinations (P values were 0.002, 0.002, and
< 0.0001 comparing to HDGF-H3 + bevacizumab, HDGF-H3 + Gem, and bevacizumab +
Gem, respectively). Tumors in 3 of the 7 animals treated with the three-agent combination
weighted less than 10 mg at the time the animals were sacrificed. These data demonstrate a
potential therapeutic utility of anti-HDGF strategy in treating lung cancer. The data also
suggest that the therapeutic strategy may be enhanced by combining with chemotherapy and
other targeted agents with distinct biological activities.
To elucidate potential mechanisms of the anti-tumor activity, we examined the tumors
obtained at the end of treatments for proliferation using Ki-67, microvessel density using
CD31, and apoptosis using TUNEL assay. We found that Ki-67 labeling index was reduced
in HDGF-H3 treated tumors (Fig. 3A and 3B), but not in bevacizumab or Gem treated
tumors. No significant reduction of Ki-67 labeling indices was observed in tumors treated
with combinations. This result suggests that the anti-tumor activity by bevacizumab and
Gem was not due to inhibition of cell proliferation. Alternatively, the proliferation capability
of the cells regained after prolonged treatment period as the tumors analyzed had been
treated for more than 2 weeks.
The microvessel density was substantially reduced in both HDGF-H3 treated (P < 0.001)
and bevacizumab treated (P < 0.001) tumors compared to M31 control antibody treated
tumors (Fig. 3C). However, the patterns of microvessel inhibition were distinctive between
HDGF-H3 and bevacizumab treated tumors. HDGF-H3 treatment appears to mainly reduce
the size or thickness of the vessels (Fig. 3D-c) whereas bevacizumab treatment substantially
reduced the vessel numbers but not the size (Fig. 3D-b), suggesting that HDGF-H3’s anti-
angiogenic activity might be independent of VEGF. It should be noted that the vessel size
observation is not quantitative and needs verification in experiments using quantitative
methods. It is well known that bevacizumab can cause fatal pulmonary hemorrhage (19,20),
which prevents its use in patients with centrally located lung cancers. Although the
mechanism of the side effect has not been fully elucidated, it is possible that the combining
the anti-HDGF antibody with bevacizumab may not only enhance their anti-angiogenic
activities but also reduce the risk of hemorrhage because the anti-HDGF agent can reduce
the vessel size and potentially prevent fatal bleeding. Surprisingly, Gem treatment increased
size of microvessels (Fig. 3D-d) and the increase was only modestly inhibited by combined
treatment with bevacizumab (P = 0.21, Fig. 3C–e) but more significantly by combined
treatment with HDGF-H3 (P = 0.04, Fig. 3C–f). Again, the inhibition was mainly through
reduction of the vessel numbers in bevacizumab treated tumors (Fig. 3D–e) but reduction of
the vessel sizes in HDGF-H3 treated tumors (Fig. 3D–f). The notion that bevacizumab and
HDGF-H3 inhibit angiogenesis through independent mechanisms is further supported by an
enhanced inhibition of microvessel density when the two agents were combined (Fig. 3D–g
and h).
An increased apoptosis was observed in Gem treated tumors, as expected, (Fig. 4A and 4B–
d) and HDGF-H3 treated tumors (Fig. 4A and 4B–c) but not bevacizumab treated tumors
(Fig. 4A and 4B-b). This result is particularly interesting because the antibody does not
trigger apoptosis nor significant growth inhibition of the cancer cells in vitro (data not
shown), suggesting a role of tumor microenvironment in HDGF-based therapeutic strategy.
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In fact, we have observed a substantial increase of apoptotic cells in tumor stroma of HDGF-
H3 treated tumors (Fig. 4C) but not in stroma of normal tissues (data not shown). Together
with the observation of HDGF-H3 induced microvessel size reduction, the data suggest a
possibility that the antibody affects paracytes surrounding the microvessels and causes
collapse of the vessels, which is consistent with the paracrine role of HDGF in smooth
muscle cells and fibroblasts (5). Combining HDGF-H3 with bevacizumab or Gem increased
apoptosis compared to the single agent alone (P = 0.004 and P < 0.001, respectively; Fig.
4A and B). These results support a utility of anti-HDGF agents in combination with
chemotherapeutic agents and other anti-angiogenesis agents.
We have previously shown that HDGF may regulate expression of a panel of genes related
to cancer cell invasion and extracellular matrix (ECM) formation, such as SERPIN2 and
AXL (15). One of the mechanisms for HDGF induced mitogenesis is its binding to a yet
identified surface receptor (16). It is possible that HDGF, secreted or released from tumor
cells, bind to the surface receptor or enter into both tumor cells and adjacent stroma cells to
function in autocrine and paracrine manner. Cytotoxic agents, such as Gem, may trigger an
increased HDGF release from tumor cells. The antibody may neutralize extracellular HDGF
and therefore shows a synergistic effect when combined with cytotoxic agents. The effect of
our strategy to tumor microenvironment is particularly significant in anti-cancer therapy and
warrants further investigation. When the anti-HDGF antibody was used together with Gem
and bevacizumab, we observed an enhanced anti-tumor activity. This is probably due to
HDGF and VEGF might play different roles in tumor angiogenesis. Therefore, simultaneous
neutralizing both growth factors might have blocked multiple mechanisms contributing to
angiogenesis and resulted in the enhanced anti-tumor activity. We are in the process to
further investigate potential mechanisms involved in the anti-tumor activity.
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Figure 1.
A, Western blot analysis testing various monoclonal antibodies developed to against HDGF
(lysate derived from H1944 cells). B, HDGF in medium conditioned with various NSCLC
cell lines (detected by using pooled monoclonal antibodies). C, distribution of the antibodies
in mice 12 hrs after IP injection. The antibodies and fluorescent dyes used are labeled next
to each mouse. The left panel was an image captured using a filter for Cy3 dye whereas the
right panel was an image captured using a filter for Cy5 dye. The arrows indicate locations
of tumors. D, distribution of the antibodies in tumor tissue sections (detected by using
specific anti-mouse IgG). Antibodies used were labeled on the side of each section for easy
reference.
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Figure 2.
A549 xenograft model. A, growth curves of tumors treated with various antibodies. B,
tumors resected at the end of the experiment. C, tumor weight measured for each treatment
groups. P values are based on comparisons to M31 control group. D, growth curves of
tumors treated with single and combination of agents indicated in the right box. G,
gemcitabine; A, bevacizumab; H, anti-HDGF-H3.
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Figure 3.
Ki-67 expression in M31 and H3 treated tumors (A) and respective Ki-67 labeling indices in
the two groups of tumors (B). Microvessel density measured by CD31 staining (C) with
examples (D). a, M31 antibody treatment; b, bevacizumab treatment; c, H3 antibody
treatment; d, Gemcitabine treatment; e, bevacizumab combined with Gemcitabine; f, H3
antibody combined with Gemcitabine; g, H3 antibody combined with bevacizumab; h, H3
antibody combined with bevacizumab and Gemcitabine. P values are based on comparisons
to M31 control group and the error bars showing as standard deviations. Green arrows
indicate microvessels with similar sizes as the controls.
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Figure 4.
TUNEL assay. A, TUNEL indices. P values are based on comparisons to M31 control group
(upper panel) and comparisons listed in the table (lower panel). The error bars represent
standard deviations. B, examples: a, M31 antibody treatment; b, bevacizumab treatment; c,
H3 antibody treatment; d, Gemcitabine treatment; e, bevacizumab combined with
Gemcitabine; f, H3 antibody combined with Gemcitabine; g, H3 antibody combined with
bevacizumab; h, H3 antibody combined with bevacizumab and Gemcitabine. C, examples
of apoptotic cells in tumor stroma were indicated by red arrows whereas the apoptotic tumor
cells were inside a black cycle.
Ren et al. Page 14
Mol Cancer Ther. Author manuscript; available in PMC 2010 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
